Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity: Preclinical characterization of a dual-masked IFN-a2b

Alexey Berezhnoy, Ph.D., Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), November 13th, 2021.